tbuckley/cabot-search huggingface dataset:
Prospective study of an AI enabled online intervention to increase delivery of guideline compliant cancer care, on the ground.
Authors: C S. Pramesh, Bhawna Sirohi, Shona Milon Nag, Sudeep Gupta, Benjamin O. Anderson, Nancy Renee Feldman, Premal H. Thaker, Sushil Beriwal, Rajendra A. Badwe
Journal: Journal of Clinical Oncology (2020)

2011 Background: Despite survival benefits of guideline compliant cancer care, under treatment and over treatment are prevalent. Navya is an AI enabled online intervention that matches a patient’s medical record with NCCN and NCG guidelines (National Cancer Grid, India) and layers live multidisciplinary expert review to recommend actionable treatment plans. It was developed to standardize care and mitigate morbidity and mortality, by delivering on-t ime, guideline based expert treatment plans. Methods: From July 2019 to January 2020, all patients who received a Navya treatment plan based on guidelines and live expert review were included. Intended treatment plans were prospectively collected from the patient. Compliance of intended plans with NCCN (including Resource Stratified Framework) or NCG was measured. Noncompliant intended plans were categorized as overtreatment or undertreatment. After delivery of Navya plan, prospective phone follow up assessed whether noncompliant intended plans were changed to guideline compliant care. Results: Of 1707 consecutive patients who received a Navya plan, 1549 intended plans were available. Patients were diverse with respect to geographic, socioeconomic, and primary tumor distribution: West of India: 28%, North: 26%, East: 21%, South: 15%, Central: 7%, International: 3%; 35% of patients with income &lt; $300/month; GI: 23%, Breast: 14%, Head &amp; Neck: 11%, Thoracic: 10%. Of the 1549 intended plans, 441 (28.47% (95% CI ± 0.26%)) were not compliant with NCCN or NCG. Undertreatment was 35%, overtreatment 26%, incomplete staging workup 28% and 11% could not be categorized. Of 441 patients with noncompliant intended plans, 80.19% (± 0.97%) shared the Navya plan with their treating oncologists and 50.40% (± 0.88%) changed their intended plan to receive the Navya treatment plan. Intervention with Navya increased on-the -ground guideline compliance by ~15% (from 71.53% ±0.42% to 85.87% ± 1.73%). Conclusions: Guideline compliant care ensures best achievable clinical outcomes with existing therapies. A technological earthshot that significantly increases adoption of guideline based care is the first step towards cancer moonshots.
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
Authors: Jesus G. Berdeja, Deepu Madduri, Saad Zafar Usmani, Indrajeet Singh, Enrique Zudaire, Tzu-Min Yeh, Alicia J. Allred, Yunsi Olyslager, Arnob Banerjee, Jenna D. Goldberg, Jordan Schecter, Dong Geng, Xiaoling Wu, Marlene Carrasco-Alfonso, Syed Rizvi, Frank (Xiaohu) Fan, Andrzej J. Jakubowiak, Sundar Jagannath
Journal: Journal of Clinical Oncology (2020)

8505 Background: JNJ-68284528 (JNJ-4528) is a chimeric antigen receptor T (CAR-T) cell therapy containing 2 BCMA-targeting single-domain antibodies. Here we present updated CARTITUDE-1 (NCT03548207) phase 1b results with longer follow-up. Methods: Pts had MM per IMWG criteria, measurable disease, received ≥3 prior regimens or were double refractory to a PI and IMiD, and received anti-CD38 antibody. Cyclophosphamide 300 mg/m 2 + fludarabine 30 mg/m 2 over 3 days were used for lymphodepletion. JNJ-4528 (median, 0.73x10 6 CAR+ viable T cells/kg) was given as a single infusion. Cytokine release syndrome (CRS) was graded by Lee et al2014 and neurotoxicity by CTCAE, v5.0 and ASTCT grading. Response was assessed per IMWG criteria. Results: As of 17 Jan 2020, median follow-up is 9 mo (3–17). Phase 1b enrollment is complete (N = 29 treated; median 5 (3–18) prior lines, 76% penta-exposed, 86% triple-refractory, 31% penta-refractory, 97% refractory to last line of therapy). Most frequent adverse events (AEs) were neutropenia (100%), CRS (93%), and thrombocytopenia (93%). Grade (Gr) ≥3 hematologic AEs were neutropenia (100%), thrombocytopenia (69%), and leukopenia (59%). 27 (93%) pts had CRS; 25 Gr 1–2, 1 Gr 3, and 1 Gr 5 (day 99 subsequent to dose-limiting toxicity of prolonged Gr 4 CRS). Median time to onset of CRS was 7 days (2–12). 4 pts had treatment-related neurotoxicity: 3 Gr 1–2 and 1 Gr 3. ORR was 100%, with 22 (76%) stringent complete responses (sCRs), 6 (21%) very good partial responses (VGPRs), and 1 (3%) PR. Median time to ≥CR was 2 mo (1–9). 26/29 pts are progression-free, with 6-mo progression-free survival rate of 93% and longest response ongoing at 15 mo. 1 death due to CRS and 1 to acute myeloid leukemia (not treatment-related) occurred during the study. All 16 pts (14 sCR, 2 VGPR) evaluable at 6 mo were minimal residual disease negative at 10 −5 or 10 −6 . JNJ-4528 CAR+ T cell expansion peaked between day 10–14. At 6-mo individual follow-up, 22/28 pts had JNJ-4528 CAR+ T cells below the level of quantification (2 cells/µL) in peripheral blood, suggesting CAR-T persistence in peripheral blood did not seem to correlate with deepening of response. At peak expansion, preferential expansion of CD8+ CAR-T cells with a central memory phenotype was observed in peripheral blood. Conclusions: JNJ-4528 treatment led to responses in all pts. These responses were early, deep, and durable at a low dose of CAR-T cells with 26/29 (90%) pts progression free at median 9-mo follow-up. CRS was manageable in most pts, supporting outpatient dosing. Clinical trial information: NCT03548207 .
Access to molecular testing and targeted molecular therapy among Mexican patients with lung adenocarcinoma.
Authors: Adriana González-Gutiérrez, Carlos Eduardo Salazar-Mejía, Edgar Dorsey-Trevino, Jose Luis Gonzalez Vela, Juan Francisco González-Guerrero, David Hernández-Barajas, Oscar Vidal-Gutiérrez, Victor Oyervides
Journal: Journal of Clinical Oncology (2020)

e19296 Background: Precision medicine has led to important changes in the treatment paradigm for patients with lung adenocarcinoma (LA) with mutations in EGFR or rearrangements of ALK or ROS1. The objective of this study is to describe the proportion of patients with LA who had access to molecular testing and targeted molecular therapy at an oncology referral center in Northeast Mexico. Methods: A retrospective study was performed with information gathered from electronic health records of the Hospital Universitario “Dr. José E. González” in Monterrey, Mexico from 2014 to 2019. Patients with LA were identified based on ICD-10 codes (C34) and diagnosis was confirmed with histopathological reports. Results: A total of 316 cases of lung cancer were identified, of which, 194 (64%) were LA, and of those, 117 (60%) had access to molecular testing. Mutations in EGFR were detected in 47%; 38% in men and 59% in women. Rearrangements in ALK were observed in 6.4%, whereas no alterations in ROS1 were seen. Access to molecular testing increased from 2014 to 2019, with a rate of 42% to 67%, respectively. Among patients that were candidates to receive targeted molecular therapy only 37% had access in 2014 versus 66% in 2019. Conclusions: The frequency of mutations in EGFR among our patients with LA showed a high discrepancy with previous studies conducted in countries with a predominantly white population. In Latin America, reports range from 14% to 34% in Argentina and Mexico, respectively. In our study, we identified a higher proportion of mutations in EGFR when compared to what previously reported; however, limited access to molecular testing may bias our results. Despite the advances in treatment for patients with LA, the availability of molecular testing and personalized treatment remains a challenge for developing countries.
Prognostic value of De Ritis ratio (aspartate transaminase/alanine transaminase) in patients with non-metastatic colorectal carcinoma [izmir oncology group(IZOG) study].
Authors: Utku Oflazoglu, Temmuz Gurdal Insan, Yuksel Kucukzeybek, Umut Varol, Tarik Salman, Yasar Yildiz, Seray Saray, Osman Butun, Halil Taskaynatan, Betul Bolat Kucukzeybek, Ahmet Alacacioglu
Journal: Journal of Clinical Oncology (2020)

e16114 Background: We aimed to assess the prognostic effect of preoperative De Ritis (aspartate aminotransaminase/Alanine aminotransaminase) ratio and pathological variables to find out whether it is an independent prognostic factor in patients with non-metastatic CRC. Methods: We retrospectively evaluated the patients who underwent curative surgery for non-metastatic CRC between 2006 and 2017. The potential prognostic value of De Ritis ratio was assessed by using a ROC curve analysis. The effect of the De Ritis ratio was analyzed by the Kaplan–Meier method and Cox regression hazard models for patients’ disease-free survival (DFS) and overall survival (OS). Results: We had 921 CRC patients in total. The univariate analysis demonstrated that low De-Ritis ratio and several well-established prognostic factors, including well-differentiated tumor,negative lymph node involvement, lymphatic invasion, perineural invasion and surgical margin, left tumor localization and early-stage tumor were good prognostic factors in terms of DFS and OS. On the multivariate analysis, De-Ritis ratio, lymph node involvement, perineural invasion status, surgical margin statusand tumor localization were independent prognostic factors for DFS [ De-Ritis ratio HR 0.468, 95% CI 0.358-0.613,p &lt; 0.001]. We also found that De-Ritis ratio, degree of differentiation, lymphatic invasion status, perineural invasion statusand stage were independent prognostic factors for OS on multivariate analysis [ De-Ritis ratio HR 0.354, 95% CI 0.407-0.702, p &lt; 0.001]. Conclusions: Our study first established a connection between the preoperative De-Ritis ratio and patients undergoing curative resection for non-metastatic colorectal cancer, suggesting that De-Ritis ratio was a simple, inexpensive, and easily measurable marker as a prognostic factor and may help to identify high-risk patients for treatment decisions.
维生素B12与中枢神经系统疾病
Authors: 李洪涛, 赵迎春
Journal: BMJ (2012)

维生素B12是一种含金属元素钴的维生素,是促进神经系统生长发育、维持神经细胞正常功能所必需的营养素.维生素B12作为同型半胱氨酸(Hey)合成蛋氨酸的辅酶,在Hcy代谢过程中起着重要作用.近年来越来越多的研究发现维生素B12在降低血液中Hcy含量,防治脑血管疾病,延缓认知功能障碍的进展等方面起着重要作用。
Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: Supplementary analysis of the JCOG trial, JCOG0502.
Authors: Seiichiro Mitani, Ken Kato, Hiroyuki Daiko, Isao Nozaki, Takashi Kojima, Masahiko Yano, Satoru Nakagawa, Masaki Ueno, Masaya Watanabe, Shigeru Tsunoda, Tetsuya Abe, Shigenori Kadowaki, Tomohiro Kadota, Haruhiko Fukuda, Ryunosuke Machida, Yuko Kitagawa
Journal: Journal of Clinical Oncology (2020)

4565 Background: Esophageal squamous cell carcinoma (ESCC) is associated with synchronous or metachronous cancer at other primary sites. Previous studies have suggested that patients (pts) with ESCC are still at a high risk of second primary malignancies after definitive therapies. In particular, early-stage ESCCs result in good prognosis, which is associated with a higher risk of second primary malignancies. Methods: The JCOG0502 was a phase III trial, which included a randomized and a non-randomized part and compared esophagectomy with definitive chemoradiotherapy in clinical T1bN0 ESCC. We additionally reviewed data of all pts enrolled in the JCOG0502 for second primary malignancies. Lugol-voiding lesions (LVLs) were assessed in the noncancerous esophageal mucosa before the treatments. Results: Among 379 enrolled pts, 213 pts received esophagectomy and the remaining received chemoradiotherapy. Patient characteristics of overall cohort were as follows: male, 85%; median age, 63 (range, 41–75) years; upper- /middle- /lower thoracic esophagus, 11/63/27%; alcohol consumption history, 79%; smoking history, 66%; prevalence of no LVLs/several LVLs/many LVLs/unknown, 45/36/8/11%. With a median follow-up of 7.1 years, a total of 118 second malignancies were observed in 99 pts (26%). Cumulative incidences of second malignancies after 3, 5, 10 years were 9, 15, 36%, respectively. Most common primary tumor sites were head and neck (35%), followed by stomach (20%) and lung (14%). In multivariable analyses, several LVLs [hazard ratio (HR): 2.24, 95% confidential interval (CI): 1.32–3.81, vs. no LVLs] and many LVLs (HR: 2.88, 95% CI: 1.27–6.52, vs. no LVLs) were significantly associated with the development of second malignancies. Regarding the three most common types of cancers, 62 out of the 77 cancers (81%) were diagnosed in clinical stage 0–I. Seventeen pts died due to second primary malignancies. There were 4 and 3 deaths from head and neck and lung cancer, respectively. Whereas, mortality caused by stomach cancer was not observed. Conclusions: In the JCOG0502, the incidence of second malignancies was high, indicating that careful follow-up is required for ESCC pts even after treatment completion. The presence of LVLs in esophagus was identified as an independent predictive factor for second primary malignancies, which may be useful for surveillance strategies. Clinical trial information: UMIN000000551 .
The results of a study of the concordance of RAS status in liquid and invasive biopsies in patients with metastatic colorectal cancer in the Republic of Kazakhstan.
Authors: Kaldigul Smagulova, Dilyara Kaidarova, Yelena Ukolova, Madina Orazgalieva, Anel Kurmankulova
Journal: Journal of Clinical Oncology (2020)

e16017 Background: Liquid biopsy is increasingly of interest as an alternative to invasive biopsy of solid tumors for predicting, making decisions about the treatment and monitoring of the disease. Particular preference is given to liquid biopsy in cases where it is not possible to obtain a sufficient amount of material or material of poor quality with a tumor biopsy. However, in order to find out the clinical significance of circulating tumor DNA (ctDNA), it is important to first establish the sensitivity of the method using tumor-plasma consistency studies. Methods: We selected 38 patients with a confirmed diagnosis of colorectal cancer (CRC), in whom was established the progression of the disease. All patients underwent two diagnostic methods, which we divided conditionally into 2 groups: A – invasive biopsy from available metastatic foci; to detect mutations in exons 2, 3, and 4 the KRAS gene used a reagent kit to detect 18 point mutations in codons 12,13,61,117,146 and a reagent kit to identify 10 mutations of the NRAS gene in codons 12,13,61,146 (Entrogen) on a Rotor-Gene 6000 Amplifier; B - liquid biopsy, to determine 21 mutations in the codons 12,13,59,61,117,146 of the KRAS gene, 18 mutations in the codons of 12,13,59,61,117,146 of the NRAS gene, was used Idylla automated molecular diagnostic system. Results: Of the 38 studied samples of group A: 22 (57.9%) had wild type KRAS, 16 (42.1%) were mutated, in group B: wild type had 25 (65.8%) patients, mutated - 13 (34, 2%). Thus, we see a discrepancy in the results in 3 (7.9%) of 38 cases. Conclusions: The results indicate a high degree of sensitivity (92.1%) of liquid biopsy as a diagnostic method, but confirmation of concordance with traditional tissue biopsy requires further in-depth study of this issue in a larger sample of patients.
Clinical features and ultrasound characteristics of benign and malignant thyroid nodules
Authors: Yan Lu
Journal: BMJ (2017)

The clinical data and ultrasound findings of 185 patients with thyroid nodules undergoing thyroidectomy from June to December 2015 were retrospectively reviewed. Postoperative pathology confirmed malignant thyroid nodules in 86 cases and benign nodules in 99 cases. The ultrasonographic findings showed that there were significant differences in obscure boundary [51% (44/86) vs.16%(16/99)], hypoecho [(95% (82/86) vs.27% (27/99)], internal micro-calcification [63%(54/86) vs.21%(21/99)] and lymph node enlargement [33%(28/86) vs.5%(5/99)] between malignant and benign nodules (all P 0.05). The results indicate that TI-RADS grading and thyroid immunity index are valuable for differential diagnosis of thyroid nodules.


Key words: 
Thyroid nodule; Ultrasonography, Doppler, color
高压氧治疗急性一氧化碳中毒迟发性脑病38例
Authors: 宋素勤, 董淑兰, 张素兰
Journal: BMJ (2009)

10%～30%的中重度一氧化碳中毒者,在经历数天、数周甚至数月假愈期后会突然出现迟发性脑病[1].而随着高压氧的应用,一氧化碳中毒迟发性脑病的治愈率越来越高.我院2005年1月至2007年12月,共收治一氧化碳中毒迟发性脑病患者38例,其中25例在常规治疗基础上加用高压氧治疗。
Effects of vaginal estrogen use on the lower urinary tract in post-menopausal women
Authors: Feng-hua Huang, Li-ping Xiao, Yi-yong Xu
Journal: BMJ (2008)

Objective To study the effects of vaginal estrogen application on blood flow of the lower urinary tract in post-menopausal women. Methods Arterial blood flow frequency spectrum, peak systolic blood flow, end-diastolic blood flow velocity and resistance index of the peri-urethra and neck of the urinary bladder, as well as changes in their genitourinary system, were measured with color Doppler ultrasound imaging in post-menopausal women before and three months after their use of premarin ointment containing natural estrogen per vagina. Results Three months after treatment with estrogen-premarin ointment per vagina in post-menopausal women, their peak systolic blood flow velocity of the peri-urethra arteries increased to 13.23 cm/s from 11.94 cm/s before treatment, end-diastolic blood flow velocity increased to 3.92 cm/s from 1.91 cm/s and resistance index decreased to 2. 79 from 3. 84 (P <0. 01 ). And, their peak systolic blood flow velocity of the arteries of the neck of the urinary bladder increased to 17.09 cm/s from 12. 77 cm/s before treatment, end-diastolic blood flow velocity increased to 2. 83 cm/s from 1.31 cm/s and resistant index decreased to 2. 78 from 3.78 (P<0.01). It indicated that local vasodilatation and decrease dresistance of the lower urinary tract made blood flow of the arteries of the peri-urethra and neck of the urinary bladder increase, urinary frequency and nocturia occurrence decrease, and sexual satisfaction improve.Conclusions Blood flow, symptoms of the lower urinary tract and their quality of life can be improved in post-menopausal women after treatment with natural estrogen-premarin ointment per vagina.

Key words: 
Menopause;  Estrogens;  Admitistration, intravaginal;  Regional blood flow; Ultrasonography, Doppler, Color
Where do women and men in Britain obtain contraception? Findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3)
Authors: French Rebecca S, Geary Rebecca, Jones Kyle, Glasier Anna, Mercer Catherine H, Datta Jessica, Macdowall Wendy, Palmer Melissa, Johnson Anne M, Wellings Kaye, 高辉
Journal: BMJ (2019)

背景
评估英国使用不同来源避孕用品的使用率及其主要人口和行为特征的变化。


方法
采用横断面概率抽样法，在2010－2012年期间，对居住在英国的16~74岁的女性和男性进行访谈。共有4 571名女性和3 142名男性，年龄16~44岁，在过去一年间有阴道性生活者接受访谈，排除已绝育(包括子宫切除术)者。避孕用品的来源分为：全科诊所、社区诊所、零售和其他。对这些来源的使用率及相关因素进行评估。


结果
在过去的一年间，87.0%的女性和73.8%的男性获得了至少一种来源的避孕用品。多数女性（59.1%）从全科诊所获取，多数男性（54.6%）从零售店获取。社区诊所的使用率较低，只有23.0%的女性和21.3%的男性从社区诊所获取，而且这些使用者更年轻，性健康风险更大。27.3%的女性和30.6%的男性使用超过一种来源避孕用品（全科诊所、社区诊所或零售），也观察到类似关联。


结论
英国人从多种途径获得避孕用品。更易受性健康风险威胁的人群更偏好一些特定的避孕用品来源。我们的结果表明，增加获得避孕措施来源这一国家政策已经起到多样化供应的效果。
Prospective agnostic germline testing in pediatric cancer patients.
Authors: Elise Fiala, Jennifer Kennedy, Yelena Kemel, Audrey Mauguen, Diana Mandelker, Ahmet Zehir, Ozge Birsoy, Nancy Bouvier, Anna Maio, Alicia Latham, Maria Isabel Carlo, Karen Anne Cadoo, Zsofia Kinga Stadler, Mark E. Robson, Neerav Narendra Shukla, Stephen S. Roberts, Andrew Kung, Kenneth Offit, Michael Francis Walsh
Journal: Journal of Clinical Oncology (2020)

1589 Background: We report our large cohort of pediatric cancer patients undergoing prospective agnostic germline sequencing. Our dataset is a significant addition to the 1,573 children reported to date who have undergone agnostic germline sequencing in previous large sequencing studies, each with ascertainment bias. Methods: 676 patients with pediatric solid tumors underwent matched tumor-normal targeted DNA sequencing from July 2015 to February 2020. At least 76 genes associated with cancer predisposition were analyzed in the germline, and variants were classified per American College of Medical Genetics guidelines. Pathogenic and likely pathogenic (P/LP) variants were reported to patients/families, who were offered genetic counseling and cascade testing with screening recommendations and referral to a surveillance clinic as appropriate. Results: One or more P/LP variants were found in 17% (115/676) of individuals when including low, moderate and high penetrance mutations in recessive and dominant genes, or 12% (81/676) when including moderate and high penetrance mutations in dominant genes. P/LP variants were detected in 40% (21/53) of patients with retinoblastomas, 8% (13/161) with neuroblastomas/ganglioneuroblastomas, 13% (14/112) with brain/spinal tumors, 8% (20/245) with sarcomas, and 12% (13/105) with other solid tumors. The most frequent mutations were in RB1 (n = 28) and TP53 (n = 8) in patients with associated tumors. Of patients with moderate/high penetrance mutations, 30% (24/81) had unexpected tumor types, with potential therapeutic relevance in 58% (14/24) including BRCA1 n = 2, BRCA2 n = 3, RAD51D n = 1, ATM n = 1 MLH1 n = 1, MSH2 n = 1, MSH6 n = 1, PMS2 n = 3, and SUFU n = 1. Two patients received immunotherapy based on their germline finding. Conclusions: P/LP germline variants are frequently present in patients with pediatric cancer. We are contributing significantly to the cohort size of agnostic sequencing in pediatric cancers. Our experience is similar to other studies with a ~12% detection rate of moderate and high penetrance mutations. Moderate/high penetrance mutations were concordant with the patient’s cancer history in 70% of cases, higher than previously reported, likely due to an enrichment of retinoblastoma. While many mutations are identified in patients with associated tumor types, a large proportion of mutations are unexpected based on the patient’s history. Clinical actionability of these findings may include screening, risk reduction, family planning, and increasingly targeted therapies.
Obstructive sleep apnea syndrome is an independent risk factor for tumor occurrence and development
Authors: Jie Cao
Journal: BMJ (2016)

阻塞性睡眠呼吸暂停综合征(OSAS)是一种常见的睡眠呼吸疾病，最近研究表明OSAS与肿瘤的发生和进展有关。流行病学调查研究首先发现，OSSA患者肿瘤的发生率和肿瘤为病因的患者死亡率增加。动物实验也相继表明OSAS模式的间歇性低氧(IH)可以促进肿瘤的生长和转移。除IH外，睡眠结构的异常和肥胖也可以促进肿瘤发生。OSAS促进肿瘤的发生和发展的结论是可以肯定的，临床医生应注意肿瘤患者是否同时也是OSAS患者，合并OSAS肿瘤患者一定要进行规范的OSAS治疗，这样才能保证肿瘤治疗的有效性和促进预后。
闭孔疝六例临床诊治分析
Authors: 王斌, 张超
Journal: BMJ (2009)

闭孔疝是腹腔内脏器经闭孔管脱出而形成的腹外疝,好发于多次妊娠及老年妇女,临床罕见,往往以严重并发症为首发症状就诊,常常不能在手术前明确诊断而行剖腹探查得以确诊,存在较高的误诊率.闭孔疝又是非常重要的急性肠梗阻原因之一,很容易发生肠嵌顿和绞窄,病死率亦较高.现将我院2001年至2008年间收治的6例典型病例临床诊治情况分析报道如下。
Ultrasonography in examining the position of gastric tube in patients undergoing gastrectomy
Authors: Zhenfeng Zhou, Long Chen, Da Yu, Lijun Huang, Meng Wu, Shuangfei Hu
Journal: BMJ (2018)

Thirty patients with gastric cancer, ASAⅡor Ⅲ, scheduled for selective radical gastrectomy under tracheal intubation general anesthesia in Zhejiang Provincial People′s Hospital from November 2016 to February 2017 were enrolled in the study. The gastric tubes were placed by a nurse before operation. The position of gastric tube was judged under gastric ultrasonography by a sonographer and anesthesiologist respectively; and confirmed by the surgeon during the operation. With the position judged by the surgeon as gold standard, the sensitivity, specificity, positive predictive value, negative predictive value of the judgment of ultrasonographer were 96%, 80%, 96%, 50%, respectively with the Kappa value 0.760 of (P<0.001), those of the judgment of anesthesiologist were 92%, 40%, 92% and 60%, respectively with a Kappa value of 0.280 (P= 0.125); those of the judgment of nurse were 92%, 0%, 100% and 71.4%, with a Kappa value of -0.105 (P=0.513). The results suggest that ultrasound examination is a simple, reliable and sensitive method for confirming correct gastric tube placement.


Key words: 
Ultrasonography; Stomach; Sensitivity and specificity